| Health / Medical Topics |
Lead Pb 212 TCMC-trastuzumab
A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab conjugated with the bifunctional chelating agent TCMC ((1,4,7,10-Tetra-(2-Carbamoyl Methyl)-Cyclododecane), and radiolabeled with the alpha-emitting isotope lead Pb 212, with potential anti-tumor activity. Upon administration, the antibody moiety of lead Pb 212 TCMC-trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2); after internalization, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to the HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed on the cell surface of a variety of cancer cell types. (NCI Thesaurus)
YOU MAY ALSO LIKE
The principal administrative organization responsible for the research conducted.
An element with atomic symbol Pb, atomic number 82, and atomic weight 207.2.
Specifies the principal entity responsible for the study.
The removal of one or more lead wires from the heart in a patient with pacemaker or implantable defibrillator.
The primary individual who over a period of time checks on and maintains continuous observation of state, condition, situation, or process relating…
Movement of a lead away from the original implantation site.
